Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Growth in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 31st total of 6,100 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 10,700 shares, the short-interest ratio is currently 1.7 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

Armata Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN ARMP traded up $0.01 during mid-day trading on Thursday, reaching $2.05. 3,615 shares of the company were exchanged, compared to its average volume of 10,464. The company has a market capitalization of $74.17 million, a P/E ratio of -1.25 and a beta of 0.85. Armata Pharmaceuticals has a 52 week low of $1.80 and a 52 week high of $4.48.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.